University of California San Diego and colleagues for the RUTH (Raloxifene Use for The Heart) trial reported in the July 13, 2006 issue of the New England Journal of Medicine a 44% decrease in invasive breast cancer risk (P=0.003) among women taking Evista was driven by a highly significant reduction in estrogen-positive breast cancer (P<0.001) but was associated with a 49% increase in the relative risk of fatal stroke (P=0.05). Evista did not reduce the risk of estrogen-negative breast cancers (P=0.40). This study did not look for ovarian cancer incidents.
In the RUTH study, Women taking Evista also had significantly more hot flushes, leg cramps, and peripheral edema (P<0.001 for all compared with placebo). For more information see http://www.askapatient.com/viewrating.asp?drug=20815&name=evista
Comment Reply
University of California San Diego and colleagues for the RUTH (Raloxifene Use for The Heart) trial reported in the July 13, 2006 issue of the New England Journal of Medicine a 44% decrease in invasive breast cancer risk (P=0.003) among women taking Evista was driven by a highly significant reduction in estrogen-positive breast cancer (P<0.001) but was associated with a 49% increase in the relative risk of fatal stroke (P=0.05). Evista did not reduce the risk of estrogen-negative breast cancers (P=0.40). This study did not look for ovarian cancer incidents.
In the RUTH study, Women taking Evista also had significantly more hot flushes, leg cramps, and peripheral edema (P<0.001 for all compared with placebo). For more information see http://www.askapatient.com/viewrating.asp?drug=20815&name=evista
February 9, 2011 - 5:39pmThis Comment
Reply